Deep TMS News - Get The Latest News On BrainsWay's Deep TMS

News & Events

March 15, 2023

BrainsWay Reports Fourth Quarter and Full-Year 2022 Financial Results and Operational Highlights

BURLINGTON, Mass. and JERUSALEM, March 15, 2023 (GLOBE NEWSWIRE) – BrainsWay Ltd. (NASDAQ & TASE:...

March 2, 2023

BrainsWay Named to Fast Company’s 2023 List of the World’s Most Innovative Companies

BURLINGTON, Mass. and JERUSALEM, March 02, 2023 (GLOBE NEWSWIRE) – BrainsWay Ltd. (NASDAQ & TASE:...

March 1, 2023

BrainsWay to Report Fourth Quarter and Full Year 2022 Financial Results on March 15, 2023

BURLINGTON, Mass. and JERUSALEM, Israel, March 01, 2023 (GLOBE NEWSWIRE) – BrainsWay Ltd. (NASDAQ &...

February 23, 2023

BrainsWay Vice President of Medical Affairs Colleen Hanlon Honored with the 2023 International Brain Stimulation Early Career Award

BURLINGTON, Mass. and JERUSALEM, Feb. 23, 2023 (GLOBE NEWSWIRE) – BrainsWay Ltd. (NASDAQ & TASE:...

February 13, 2023

BrainsWay Announces Appointment of Hadar Levy as CEO

BURLINGTON, Mass. and JERUSALEM, Feb. 13, 2023 (GLOBE NEWSWIRE) – BrainsWay Ltd. (NASDAQ & TASE:...

February 13, 2023

BrainsWay Announces Appointment of Ami Boehm as New Chairman

David Zacut, M.D., Relinquishing Chairman Role Held Since Company’s Inception, to Now Serve as Board...

January 31, 2023

Publication Analyzes Clinical Efficacy of Deep TMS™ in Treating Different Brain Regions Associated with Major Depressive Disorder

Study Results Outline a Potential Path to More Personalized Medicine in Noninvasive Brain Stimulation BURLINGTON,...

January 11, 2023

BrainsWay Announces Extended Private Insurance Coverage in Washington State for the Treatment of OCD and Depression Utilizing Deep TMS™

BURLINGTON, MA and JERUSALEM, Israel, Jan. 11, 2023 (GLOBE NEWSWIRE) – BrainsWay Ltd. (NASDAQ &...

January 10, 2023

BrainsWay Resolves Neuronetics Litigation

BURLINGTON, Mass. and JERUSALEM, Jan. 10, 2023 (GLOBE NEWSWIRE) – BrainsWay Ltd. (NASDAQ & TASE:...

December 13, 2022

BrainsWay Reports Open Market Stock Purchase by Board Member Yossi Ben Shalom

BURLINGTON, Mass. and JERUSALEM, Dec. 13, 2022 (GLOBE NEWSWIRE) – BrainsWay Ltd. (NASDAQ & TASE:...

November 28, 2022

BrainsWay Reports Open Market Stock Purchases by Two Board Members

BURLINGTON, Mass. and JERUSALEM, November 28, 2022 (GLOBE NEWSWIRE) – BrainsWay Ltd. (NASDAQ &...

November 16, 2022

BrainsWay Reports Third Quarter 2022 Financial Results and Operational Highlights

Conference call to be held today, November 16, 2022, at 8:30 AM ET                       ...

November 3, 2022

BrainsWay Announces Private Insurance Coverage from Premera Blue Cross for the Treatment of OCD Utilizing Deep TMS™

Reflects Broader Trends Significantly Increasing Access to Deep TMS for OCD and Depression Patients BURLINGTON,...

November 2, 2022

BrainsWay to Report Third Quarter Financial Results on November 16, 2022

BURLINGTON, Mass. and JERUSALEM, Nov. 02, 2022 (GLOBE NEWSWIRE) – BrainsWay Ltd. (NASDAQ & TASE:...

November 1, 2022

BrainsWay Appoints Dr. Colleen A. Hanlon as Vice President of Medical Affairs

Dr. Hanlon has Served as a Leader in Brain Stimulation Research for Nearly 20 Years BURLINGTON, Mass....

October 12, 2022

BrainsWay Launches Social Media Sweepstakes in Observance of Depression Awareness Month

The sweepstakes aims to raise awareness of Deep TMS™ as a treatment option for mental health disorders...

October 11, 2022

BrainsWay and NOCD Launch Collaboration to Increase Awareness of OCD Treatments

BURLINGTON, Mass. and JERUSALEM, Oct. 11, 2022 (GLOBE NEWSWIRE) – BrainsWay Ltd. (NASDAQ & TASE:...

September 20, 2022

BrainsWay CEO Christopher von Jako Named Honorary Chair of NAMIWalks Silicon Valley

BURLINGTON, Mass. and JERUSALEM, Sept. 20, 2022 (GLOBE NEWSWIRE) – BrainsWay Ltd. (NASDAQ & TASE:...

Find a provider near you or contact us today.

Find a Provider Contact Us